AbbVie Inc (ABBV) : Gierl Augustine Investment Management Inc scooped up 709 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 14, 2016. The investment management firm now holds a total of 47,267 shares of AbbVie Inc which is valued at $2,844,055.AbbVie Inc makes up approximately 2.67% of Gierl Augustine Investment Management Inc’s portfolio.
Other Hedge Funds, Including , Patten Patten Inctn reduced its stake in ABBV by selling 9,124 shares or 3.95% in the most recent quarter. The Hedge Fund company now holds 221,813 shares of ABBV which is valued at $13,838,913. AbbVie Inc makes up approx 1.81% of Patten Patten Inctn’s portfolio.New England Research Management reduced its stake in ABBV by selling 11,700 shares or 75.44% in the most recent quarter. The Hedge Fund company now holds 3,808 shares of ABBV which is valued at $241,389. AbbVie Inc makes up approx 0.20% of New England Research Management’s portfolio.
AbbVie Inc closed down -0.98 points or -1.60% at $60.17 with 56,06,474 shares getting traded on Friday. Post opening the session at $61.45, the shares hit an intraday low of $60.15 and an intraday high of $61.515 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by JP Morgan to ” Neutral” on Sep 8, 2016. Raymond James Initiated AbbVie Inc on Sep 2, 2016 to “Outperform”, Price Target of the shares are set at $82.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.